Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2009 January 5; 119(1): 182–192.
Published online 2008 December 22. doi:  10.1172/JCI36470
PMCID: PMC2613467

Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease


Parkinson disease (PD) is a neurodegenerative disorder characterized by a loss of dopamine-containing neurons. Mounting evidence suggests that dopaminergic cell death is influenced by the innate immune system. However, the pathogenic role of the adaptive immune system in PD remains enigmatic. Here we showed that CD8+ and CD4+ T cells but not B cells had invaded the brain in both postmortem human PD specimens and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD during the course of neuronal degeneration. We further demonstrated that MPTP-induced dopaminergic cell death was markedly attenuated in the absence of mature T lymphocytes in 2 different immunodeficient mouse strains (Rag1–/– and Tcrb–/– mice). Importantly, similar attenuation of MPTP-induced dopaminergic cell death was seen in mice lacking CD4 as well as in Rag1–/– mice reconstituted with FasL-deficient splenocytes. However, mice lacking CD8 and Rag1–/– mice reconstituted with IFN-γ–deficient splenocytes were not protected. These data indicate that T cell–mediated dopaminergic toxicity is almost exclusively arbitrated by CD4+ T cells and requires the expression of FasL but not IFNγ. Further, our data may provide a rationale for targeting the adaptive arm of the immune system as a therapeutic strategy in PD.


Parkinson disease (PD) is a neurodegenerative disorder characterized by the loss of dopamine-containing neurons (DNs) in the substantia nigra (SN) pars compacta (SNpc). Except for rare genetic forms, PD is a sporadic condition of unknown cause. Yet, several scenarios regarding the mechanisms by which DNs degenerate have been suggested, including mitochondrial dysfunction, oxidative stress, and the impairment of protein degradation machinery (1). In addition to these well-established pathomechanisms, there is mounting evidence from epidemiological, postmortem, and animal studies to suggest that innate neuroinflammatory processes associated with glial cell activation participate in the progression of DN cell death (26).

Far more enigmatic is the putative role of the adaptive immune system in PD pathogenesis. While several changes in cellular and humoral immune responses have been described in the peripheral immune system of PD patients, it remains unclear whether these alterations are primarily involved in the etiogenesis of PD or simply reflect secondary consequences of nigrostriatal pathway injury (5). Up to now, the hypothesis that the cellular arm of the adaptive immune system plays a role in neurodegeneration has been hampered by the fact that no clear demonstration of a prominent involvement of leukocytes at the site of neuronal injury has been provided in PD. Yet, the reports many years ago that cytotoxic T cells (Tc) can be found in massive numbers in the SN of a patient with PD (7) and that the density of IFN-γ–positive cells is markedly increased in brains of patients of with PD (8), suggest that T cell brain recruitment may be associated with nigrostriatal pathway injury in PD. In support of this view is the demonstration that the accumulation of T cells in the brain can be stimulated in mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine–induced (MPTP-induced) DN injury (9). Yet, whether this immune response truly contributes to neurodegeneration and, if so, by what mechanisms remains to be established.

In this study, we sought to determine whether PD is associated with leukocyte brain infiltration within the affected SN region and, if so, whether this process contributes to DN degeneration. We found that both CD8+ and CD4+ T cells significantly invade the SN in postmortem specimens from patients with PD and in MPTP-intoxicated mice. We also show that removal of CD4+ but not of CD8+ T cells in mice greatly reduced MPTP-induced nigrostriatal DN cell death. Finally, we further demonstrate that the deleterious activity of infiltrated CD4+ T cells involved the Fas/FasL pathway but not Ifn-γ production.


Lymphocyte brain infiltration in PD patients.

To test the possibility that leukocytes infiltrate the brain parenchyma of PD patients, we performed immunohistochemical staining for various leukocyte-specific markers (10) on postmortem human brain (for antibody description, see Supplemental Table 1; supplemental material available online with this article; doi: 10.1172/JCI36470DS1). Positive staining was observed for CD8 and CD4 but not for B cell and NK cell markers. Within the SNpc, CD8+ and CD4+ T cells were found either in close contact with blood vessels or in the vicinity of melanized DNs (Figure (Figure1,1, A and B). These cells displayed a typical lymphocyte morphology that was further confirmed by electron microscopy analysis. At the ultrastructural level, parenchymal CD8+ T cells displayed small cytoplasmic volume, membrane-type CD8 staining, and, in some cases, uropod-like cytoplasmic extension, usually involved in T cell motility (Figure (Figure1C).1C). Importantly, quantitative analysis revealed a significant increase (10-fold in average) in the density of CD8+ and CD4+ T cells in the SNpc but not in the nonlesioned red nucleus from PD patients compared with age-matched control subjects (Figure (Figure1D1D and Supplemental Table 2).

Figure 1
Lymphocyte infiltration in brains of patients of with PD.

MPTP-induced DN lesion stimulates extravasation of lymphocytes into the brain.

The above data suggest that migration of peripheral lymphocytes within the CNS is associated with nigrostriatal pathway injury in PD. Yet, although postmortem studies in humans are essential to establish that immune cell infiltration is characteristic of the disease, they cannot provide information about the dynamic and functional relevance of such mechanisms. To address this issue, we conducted in vivo experiments using the well-characterized MPTP-intoxicated mouse model of PD (1). Although it is not a phenocopy of human disease, this noninvasive model provides a unique means to study non-cell autonomous pathomechanisms, as it recapitulates many of the hallmarks of PD, including DN loss, attenuation of striatal dopamine, and glial cell–associated inflammatory processes. To easily track the migration of peripheral leukocytes independently of their phenotypic traits, we first used a passive transfer strategy that consisted of transferring GFP-tagged T or B cells into recombinase activating gene 1–deficient (Rag1-deficient) mice, which lack mature lymphocytes. Recipient animals with reconstituted lymphoid organs were then treated with MPTP or saline solution (Figure (Figure2A2A and Supplemental Figure 2). Unlike GFP+ B cells (data not shown), we found GFP+ T cells in the SNpc and striatum after MPTP treatment (Figure (Figure2,2, B and C). Most, if not all, other brain structures but DN-containing regions were devoid of T cell infiltrate, indicating the region-specific extravasation of these immune cells (Supplemental Figure 3). Brain sections immunostained for tyrosine hydroxylase (TH) show GFP+ T cells within the SNpc clustered in close proximity to TH-expressing DNs (Figure (Figure2D).2D). Furthermore, infiltrated T cells had clearly transmigrated through the brain parenchyma, since most of them were found to be excluded from the lumen of blood vessels identified by Glut1 immunostaining (Figure (Figure2D).2D). Finally, both CD8+ and CD4+ T cell subtypes were found to be recruited (Figure (Figure2D). 2D).

Figure 2
MPTP-induced nigrostriatal pathway injury stimulates T cell brain infiltration in mouse.

To ensure that the infiltration of T cells into the brain observed in our graft-based experimental model was not merely an artifact related to the methodology, we looked at leukocyte transmigration in MPTP-intoxicated C57BL/6J inbred mice, using immunohistochemistry for the T cell–specific marker CD3. In these conditions, a similar T cell infiltration process was observed (Figure (Figure2E).2E). When compared with the time course of glial cell activation, CD3+ T cell brain infiltration was found to arise after the increase of CD11b+ microglial cells (i.e., 12 hours post-MPTP intoxication) but concomitantly with astrogliosis (Supplemental Figure 4). Consistent with our postmortem findings, nigral CD8+ T cells were more abundant than CD4+ T cells, and transmigration occurred at day 2 after treatment, increased continuously for up to 7 days, and had totally ceased at 21 days (Figure (Figure2E).2E). Such dynamics are therefore compatible with a possible role of activated microglial cells in the brain region–specific recruitment of T cells.

The continuous nigral accumulation of T cells indicates that lymphocytes could clonally expand into the brain parenchyma. To test such a possibility, we surveyed the expression of proliferating cell nuclear antigen (PCNA), taken as a marker of dividing cells, at 0.5, 1, 2, 4, and 7 days after the last MPTP injection. As shown in Figure Figure2F,2F, while we observed numerous PCNA+ cells in the SNpc after MPTP intoxication, none of them were found to colocalize with either GFP+ T cells or glial fibrillary acidic protein–positive (GFAP-positive) astrocytes at all the time points analyzed. Instead, most of these cells also expressed the myeloid marker CD11b, suggesting that infiltrated macrophages and/or resident microglial cells multiply at the site of injury. Thus, accumulation of T cells may indicate a continuous extravasation process, at least up to 7 days after neurotoxin exposure. Yet, the number of CD3+ T cells within the SNpc was found to dramatically decrease shortly after this accumulation (i.e., at day 9) (Supplemental Figure 5A), raising the possibility that they could be rapidly eliminated by apoptotic cell death due to regulatory mechanisms aimed at terminating the immune response. To test this, we looked for morphological criteria as well as molecular changes indicative of apoptosis in the entire SNpc and ventral tegmental area of animals sacrificed 7 and 9 days after systemic MPTP administration. Immunohistochemistry for CD3 coupled with thionin counterstaining revealed the presence of apoptotic cells characterized by shrinkage of cellular body, chromatin condensation, and presence of distinct, round, well-defined chromatin clumps (Supplemental Figure 5B). Whereas apoptotic cells were found in all MPTP-treated mice analyzed at day 7 and 9 (n = 10 and 5, respectively), they were not observed in saline-injected controls. In few instances, these cells have retained some CD3 staining, attesting their T cell origin (Supplemental Figure 5C). Additional evidence for T cell apoptosis was obtained from double immunofluorescence staining for CD3 and activated caspase-3. Thus, some CD3+ T cells were found to be positive for the p17 fragment of activated caspase-3 (Supplemental Figure 5D).

Since a previous report indicated that the blood-brain barrier (BBB) may be dysfunctional in PD patients (11), we examined whether MPTP-associated BBB disruption could account for a passive entry of lymphocytes into the brain. A time course of BBB leakage from 6 hours to 7 days after MPTP administration was determined by assessing serum albumin and immunoglobulin extravasation. Our data reveal that MPTP induces a widespread and transitory serum protein leakage (detectable at 6 hours but absent from 12 hours after MPTP treatment), contrasting therefore with the cell type– and region-specific leukocyte extravasation process (Figure (Figure3A).3A). To further explore the mechanism of T cell extravasation, we surveyed the expression of ICAM-1/CD54, an immunoglobulin-like cell adhesion molecule, involved in leukocyte adherence and transendothelial migration at sites of inflammation (12). Whereas CD54 was barely detectable in controls (data not shown), we observed a marked increase in CD54 immunostaining within the SNpc at the site of T cell infiltration following MPTP intoxication (Figure (Figure3B).3B). Blood vessels, glial cells, and T cells were all intensely positive, indicating possible cross-interactions among these cellular actors.

Figure 3
Mechanism of lymphocyte entry into the brain.

Mice deficient in cell-mediated immunity are more resistant to MPTP.

Investigations dedicated to unraveling the role of infiltrated T cells in various models of neuronal injury have led to opposite conclusions (13, 14). To determine whether T cell accumulation in the SNpc following MPTP intoxication is beneficial or harmful to DNs, we compared the effects of the toxin in T cell receptor β chain mutant mice lacking mature T lymphocytes (Tcrb–/–) (15) and in their WT littermates. We found that whereas only 72% of the nigral TH+ DNs survived MPTP injection in WT mice, 91% of these neurons survived in Tcrb–/– mice treated with a similar MPTP regimen (Figure (Figure4,4, A and B). Importantly, the decrease in MPTP-induced DN loss in Tcrb–/– mice correlated with a reduction in the number of infiltrated T cells to a level similar to that of saline-injected animals (Figure (Figure4C).4C). Residual T cell infiltration in Tcrb–/– mice may come from the small number (about 8% of the WT level) of cells remaining in the thymus of these mutants (15).

Figure 4
Mice deficient in CD4+ T cells are more resistant to MPTP.

Given the apparent harmful behavior of infiltrated T cells, we next investigated whether CD8+ and/or CD4+ T cells could mediate such a detrimental function. To that end, we intoxicated mice homozygous for either a targeted mutation of Cd8a or Cd4, characterized by a deficiency in functional Tc and Th, respectively (16, 17). Whereas MPTP induced a comparable level of DN cell death in Cd8a–/– mice as in WT littermates, we observed a marked reduction in TH+ cell loss in Cd4–/– mice (Figure (Figure4,4, A and B). Interestingly, the rate of DN survival in Cd4–/– mice was comparable to that of Tcrb–/– animals, suggesting that most of the deleterious outcome associated with infiltrated T cells is mediated by the CD4+ Th subset. In support of this idea, susceptible WT and Cd8a–/– mice exhibited a similar number of infiltrated CD4+ T cells following MPTP exposure (Figure (Figure4C).4C). However, there were no significant differences in the extent of loss in striatal levels of dopamine, 3-4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) between mutant mice and their WT littermates after the administration of MPTP, implying that striatal T cell infiltration is not a major component of dopaminergic fibber injury (Table (Table1).1). Importantly, reduced MPTP metabolism in mutant mice is not likely to account for the observed neuroprotection, as striatal 1-methyl-4-phenylpyridinium (MPP+) content after a single systemic MPTP injection did not differ between genotypes (Table (Table2).2). Moreover, consistent with the partial resistance of Tcrb–/– and Cd4–/– mice to MPTP, midterm (2–7 days) microglial cell activation was almost completely abolished in mutant mice (Figure (Figure4B). 4B).

Table 1
Striatal monoamine levels (pM/mg tissue)
Table 2
Striatal MPP+ content after MPTP injection

The Fas/FasL pathway is required for CD4 T cell–dependent DN toxicity.

The finding that CD4-deficient mice are partially protected against MPTP-induced injury suggests that Th-mediated deleterious mechanisms are engaged and instrumental in DN demise. Cytokines, including IFN-γ, and membrane bound ligands, such as FasL, represent 2 major classes of molecules mediating effector functions of CD4 Th (e.g., macrophage activation). Interestingly, it has been shown that IFN-γ was a contributing factor in the death of DNs by regulating microglial activity (18). In fact, we found that IFN-γ expression was upregulated in the ventral midbrain 2 days after MPTP exposure, which coincided with the first wave of CD4+ T cell brain infiltration (Supplemental Figure 6A). To analyze the putative deleterious role of lymphocyte-derived IFN-γ, we passively transferred total splenocytes isolated from either WT or IFN-γ–deficient mice into recipient Rag1–/– animals. Consistent with the deleterious role of T cells as previously evidenced in Tcrb–/– mice, we noticed that MPTP-induced injury in immunodeficient Rag1–/– mice was significantly less severe than in WT littermates (Figure (Figure5,5, A and B). Importantly, this partial resistance was completely reversed when spleen cells from either WT or Ifng–/– mice were passively transferred prior to MPTP intoxication (Figure (Figure5A).5A). Thus, lymphocyte-derived IFN-γ is not likely to be required for T cell–mediated DN cell death. In support for this assertion, Ifng–/– mice and their WT littermates were found to be equally sensitive to MPTP-induced DN cell death using an identical intoxication paradigm (Supplemental Figure 6B). Therefore, we next considered the involvement of a Fas-based mechanism. To test this, we took advantage of the FasL-mutated generalized lymphoproliferative (gld) mice that bear a point mutation in the extracellular domain of FasL (CD95L), resulting in a dramatic decrease of affinity to its receptor Fas (19). Thus, we compared the MPTP susceptibility of Rag1–/– recipients that received spleen cells from either gld or C57BL/6J donors (designated gld rec. Rag1–/– and WT rec. Rag1–/–, respectively). In WT rec. Rag1–/– mice, MPTP caused as much DN loss as in WT animals (Figure (Figure5,5, A–C). In sharp contrast, both nonreconstituted Rag1–/– and gld rec. Rag1–/– mice exposed to a similar dose of MPTP exhibited a significantly smaller reduction in the number of nigral DNs (Figure (Figure5,5, B and C). The protection gained in gld rec. Rag1–/– mice was consistently within a similar range to that observed in Cd4–/– animals (Figure (Figure4A4A and Figure Figure5B).5B). Furthermore, this protective effect was not likely due to altered extravasation potency of gld-derived splenocytes, as a similar number of brain infiltrated CD4+ T cells were observed between MPTP-treated WT rec. Rag1–/– and gld rec. Rag1–/– animals (mean number of CD4+ T cells in the SNpc ± SEM, 81.6 ± 22.5 and 95.5 ± 38.2, respectively; P = 0.55, Mann-Whitney U test). Together, these results suggest that CD4+ Th-mediated DN cell death requires the expression of a functional FasL but not IFN-γ.

Figure 5
FasL, but not IFN-γ, is required for T cell–mediated DN toxicity in MPTP mouse.


Mounting evidence supports the notion that innate immunity significantly contributes to dopaminergic neurodegeneration in PD (1). By contrast, although altered cellular and humoral functions have been reported in the peripheral immune system of PD patients, the role of adaptive immunity in the pathogenesis of this disorder has remained much more elusive (5, 20). Among these peripheral immune changes, the significant increased ratio of CD8+ Tc to CD4+ Th and of IFN-γ–producing to IL-4–producing T cells suggests the existence of a disease-associated shift to a Tc1/Th1-type immune response, which may reflect and/or contribute to the harmful brain inflammatory reaction (21). Nonetheless, a role for the cellular arm of the adaptive immune system in neurodegeneration is curbed by the fact that no clear demonstration of a prominent involvement of leukocytes at the site of neuronal injury has been provided in PD. In this study, we present evidence that peripheral T cells migrate to and accumulate in the brain parenchyma during parkinsonism. Importantly, we have shown that CD4+ but not CD8+ T cells are deleterious to DNs, which suggests that the adaptive immune system may contribute to disease progression in PD.

It is now well established that the CNS is not only continuously monitored by T cells (22) but also massively invaded by peripheral leukocytes in neuropathological circumstances (23). In agreement with the seminal but rather preliminary observation by McGeer and colleagues, showing a substantial presence of CD8+ T cells in the brain from one PD case (7), we now provide strong quantitative evidence from a large number of individuals that both CD8+ and CD4+ T lymphocytes markedly accumulate in the SNpc of PD patients. Consistent with a previous report (9), we found that experimental lesion of the nigrostriatal pathway in MPTP-intoxicated mice results in a similar brain accumulation of T cells. Yet, brain accumulation of T cells following MPTP intoxication was not restricted to the SNpc. Indeed, other catecholaminergic areas known to be moderately injured following MPTP treatment (24) were also invaded, albeit to a lower extent. This extravasation of lymphocytes is not likely to be a generalized nonspecific leukocyte response, as (a) other leukocyte subsets, including B cells and NK cells, were not detected in the lesioned SNpc, and (b) an increased occurrence of T cells was not observed in nonlesioned brain areas, suggesting that this process does not simply reflect an overall enhancement of lymphocyte patrolling. Altogether, these findings indicate that, as with the glial cell reaction previously described, T cell brain infiltration in PD most certainly represents a secondary and highly regulated pathogenic event associated with neuronal cell death. Such a cellular and site-specific brain immune response is not likely to be caused by a massive disruption of the BBB, for which little evidence exists in PD (25, 26) and which remains controversial in MPTP-intoxicated mice (27, 28). We showed a widespread BBB leakage that occurred shortly (6 hours) after neurotoxin exposure and was rapidly resolved (by 12 hours after MPTP treatment), well before lymphocytic invasion. Taken together, these findings argue that lymphocyte brain infiltration is not a passive phenomenon. Instead, molecular and cellular changes associated with neuronal injury are likely to regulate this site-specific brain recruitment of T cells. Possible mechanisms may involve early microglial cell activation and innate neuroinflammatory processes that could modify the local microenvironment. In line with this, we found an upregulated expression of the ICAM-1 adhesion molecule on both capillaries and glial cells, which may participate in the attachment of leukocytes to the vascular endothelium and their diapedesis (29). Interestingly, a similar ICAM-1 overexpression was recently described in both the SN of patients with PD and MPTP-intoxicated monkeys (30). Although the level of T cell brain accumulation was found to be higher in the disease model than in PD patients, one has to consider that the human disease progresses over several decades, whereas it only lasts 1 to 2 weeks in mouse model. Moreover, investigations performed on human postmortem tissue most often address late pathomechanisms and can not therefore predict the intensity of the lymphocyte infiltration process, which might be greater during earlier stages of the disease. Given that incidental Lewy body disease is considered by some authors to be a presymptomatic form of PD (31), it might be valuable to explore such lymphocytic invasion in those patients. Finally, it is worth noting that the distribution of T cell accumulation within the SNpc from PD patients is much more heterogeneous than that in MPTP mice. Indeed, in few instances, as shown in Figure Figure1,1, infiltrating T cells in brains of patients of with PD were found to be clustered around the few remaining pigmented DNs, whereas they were virtually absent in advanced depigmented areas. Such distribution suggests that the number of T cells reaching the target neurons is conceivably substantial and strengthens their possible involvement in DN cell demise.

A major contribution of our study is the demonstration that infiltration of T cells into the brain actively participates in DN degeneration. A decreased vulnerability of DNs to MPTP toxicity associated with the removal of mature T lymphocytes was achieved by 2 different genetic immune defects (Rag1–/– and Tcrb–/–), thus supporting a role for the cellular arm of the adaptive immune system in experimental parkinsonism. Our results are in agreement with a recent study, showing a similar neuropathological improvement in MPTP-intoxicated SCID mice (32). Notably, our data further reveal that different T cell subsets do not contribute equally to DN cell death. Indeed, while the predominance of infiltrated CD8+ over CD4+ T cells was consistently observed both in PD patients and MPTP-intoxicated mice, removal of the CD8+ T cell subset in Cd8a–/– mice did not mitigate MPTP injury. In sharp contrast, the Th deficiency achieved in Cd4–/– mice conferred as much neuroprotection as in Rag1–/– and Tcrb–/– animals, suggesting that CD4+ T cells mediate most if not all the deleterious activity associated with the adaptive immune response.

Since infiltrated T cells highly express ICAM-1 as well as lymphocyte function-associated antigen-1 (LFA-1) and CD44 (9, 30), we believe that most of them could be recruited from an activated/memory population. A mechanism of peripheral leukocyte activation secondary to MPTP intoxication has recently been proposed (32). In this model, nitrotyrosine modification within α-synuclein (α-Syn) promotes an antigen-specific T cell response in draining lymph nodes. After migrating into the injured brain areas, these antigen-specific T cells could undergo further activation and promote microglial cell–dependent neurodegeneration through cytokine release. Although the differential contribution of CD8+ versus CD4+ T cells in this deleterious immune response was not addressed by the authors, their prediction analysis of α-Syn–specific T cell epitopes suggested a significant potential for CD4+ T cells of mice expressing IAk or IAb MHC class II molecules to respond to nitrated epitopes of α-Syn. These data, taken in conjunction with our present findings, support a model in which MPTP-induced brain antigen modification most likely generates a secondary and harmful Th response contributing to DN degeneration.

Looking at the cytotoxic mechanism mediated by the CD4+ T cell response following nigrostriatal pathway injury, we found that T cell expression of FasL but not IFN-γ was required. It has been shown that IFN-γ is critical in microglial-mediated loss of DNs in MPTP-intoxicated mice (18). Yet, using 2 different experimental approaches, i.e., total and cell-specific IFN-γ deletion, we were unable to show a major role for this proinflammatory cytokine in DN cell demise. While the reason for such a discrepancy is still not clear, a lack of IFN-γ expression in our disease model could not be incriminated. Indeed, in agreement with a previous report (33), we were able to detect a rise in IFN-γ following MPTP-induced nigrostriatal pathway injury. Whether different treatment protocols lead to distinct involvement of IFN-γ in disease models will need further clarification.

The requirement of FasL in CD4+ T cell–mediated cytotoxicity is consistent with the finding that Fas-deficient mice display attenuated MPTP-induced DN loss (34), although another study has come to a different conclusion (35). Whereas, in the context of antigen presentation, the Fas/FasL pathway has been implicated in the deletion of activated macrophages, thereby contributing to the resolution of inflammation (36), recent evidence suggests that this pathway may instead induce proinflammatory cytokine responses in tissue macrophages (37). CD4+ Th FasL-mediated activation of microglial cells could therefore participate in the inflammatory reaction and DN degeneration. T cell–derived FasL may also mediate inflammatory responses in astrocytes, which are known to be particularly resistant to Fas-mediated cell death and express proinflammatory cytokines and chemokines upon Fas ligation (38). In line with this, Fas expression has been shown to be upregulated on these glial cells both in PD patients and in the MPTP model (34, 39). Alternatively, infiltrated CD4+ T cells may also induce DN cell demise through cell-cell contact. Such a mechanism has previously been shown in vitro, in which antigen primed CD4+ or CD8+ T cells induced neuronal death independently of antigen presentation and involved cell surface expression of FasL by activated T cells (40). Further investigations will be required to determine whether or not CD4+ T cell–mediated cytotoxicity relies strictly on MHC-dependent antigen presentation.

In our disease model, the finding that harmful lymphocyte response is CD4 T cell–dependent but IFN-γ–independent raises important but still unresolved concerns about the phenotypic characteristics of these CD4 T cells. Although these observations would not favor the contribution of a Th1-type response, one can not exclude the possibility that CD4+ Th1 cells may mediate cytotoxicity independently of IFN-γ as previously reported (40, 41). In particular, the role of other proinflammatory Th cytokines, such as TNF-α in T cell–mediated DN cell death, should also be considered as a potential deleterious mechanism, even though the role of this factor is still debated (4244). Finally, another tantalizing possibility could be the involvement of an alternative inflammatory CD4 T cell population, namely, the recently described, Th17 cells. A growing body of evidence indicates that Th17 cells play a critical function not only in protection against microbial challenges but also in many organ-specific autoimmune diseases, including multiple sclerosis and its disease model experimental autoimmune encephalomyelitis (45). In line with this, it has recently been shown that Th17 cells have the potential of killing neurons, probably through the granzyme B cytolytic enzyme system (46). Whether such a CD4 T cell subset is implicated in parkinsonism as well merits further considerations.

It is worth noting that the CD4+ T cell response to neurodegenerative processes can differently affect disease outcome. Indeed, while in the MPTP mouse model of PD, CD4+ T cells are likely harmful to DNs (Figure (Figure4A4A and ref. 32), it has recently been documented that this T cell population can provide supportive neuroprotection in animal model of inherited amyotrophic lateral sclerosis (ALS), by stimulating the trophic properties of glia (47). Interestingly, such pathological improvement can be recapitulated by delivering activated regulatory or effector T cells to ALS mice but not by Copolimer-1 immunization, indicating that antigen-driving Th2/Th3 responses are impaired in this animal model (48). Thus, different neurodegenerative contexts could result in distinct T cell responses, which in turn may positively or negatively influence disease progression. Undoubtedly, a better phenotypic characterization of these CD4+ T cell subsets should improve our understanding of the role of the adaptive immune system in various neurodegenerative conditions.

In summary, we have shown that peripheral T cells infiltrate the brain parenchyma at the site of neuronal injury both in PD patients and in experimental parkinsonism. We have demonstrated that this cell-mediated immune response contributes to DN cell degeneration through a CD4+ T cell–dependent Fas/FasL cytotoxic pathway. Our results, together with recent investigations (32), provide further rationale for targeting the adaptive arm of the immune system in PD. Therapeutic strategies may involve developing vaccines for antigens that promote cell-mediated antiinflammatory responses (49, 50) as well as blocking the migration of immune cells across the BBB (51). Besides providing potential neuroprotective benefits for the remaining DNs, these immunomodulatory strategies may also be of interest for cell transplantation therapies, as long-term survival of grafted DNs, which eventually undergo PD-related pathological changes over time, could be jeopardized by such an immune-related hostile microenvironment (52).


Human samples.

The study was performed on autopsy brainstem tissue (Hôpital de la Salpêtrière) from 8 control subjects and 14 parkinsonian patients, which were well-characterized clinically and neuropathologically. PD patients and control subjects did not differ significantly in terms of their mean age at death (PD patients, 77.85 ± 2.11 years of age; controls, 76.62 ± 3.72 years of age; P = 0.76, Student’s t test; mean ± SEM) or the mean interval from death to the freezing of tissue (PD patients, 40.55 ± 3.80 hours; controls, 28.10 ± 7.08 hours; P = 0.11, Student’s t test; mean ± SEM). Experiments using human postmortem material were approved by the Comité de Protection des Personnes review board (Ile de France 1, Paris, France). Due to limited accessibility to tissue sections, different numbers of patients were analyzed with respect to each leukocyte marker. Tissue was fixed in formaldehyde and then embedded in paraffin. Paraffin-embedded tissues were cut in serial 8-μm thick slices on a microtome, and sections were recovered on SuperFrost Plus slides (Kindler O GmbH), before incubation at 56°C for 3 days. Human tonsil slices (Dako) were used as tissue control for lymphoid marker immunohistochemistry.


Ten- to twelve-week-old male C57BL/6J mice, weighing 25–30 g (CERJ) were used. The following strains were obtained from The Jackson Laboratory: B6.129S6-Cd4tm1Knw/J, B6.129S2-Cd8atm1Mak/J, B6.129P2-Tcrbtm1Mom/J, B6.129S7-Rag1tm1Mom/J, B6.129S7-Ifngtm1Ts/J, B6Smn.C3-Faslgld/J, and corresponding parental WT inbred C57BL/6J. Mice were kept in a temperature-controlled room (23°C ± 1°C) under a 12-hour light/dark cycle and had ad libitum access to food and water. All animals were further genotyped after their sacrifice according to The Jackson Laboratory protocols. GFP+ cells were isolated from double Tie2-Cre+/ZEG+ transgenic mice (designated GFP-Tg), in which the GFP reporter gene is expressed in early hematopoietic cell precursors (53). Animal handling was carried out according to ethical regulations and guidelines (Guide for the care and use of laboratory animals. NIH publication no. 85-23. Revised 1985) and the European Communities Council Directive 86/609/EEC. Experiments using vertebrates were approved by the Services Vétérinaires de Paris.

Treatment and tissue preparation.

Groups of mice received 4 i.p. injections of MPTP-HCl (20 mg/kg, except where otherwise stated) at 2-hour intervals and were sacrificed from 6 hours to 21 days after the last injection. Control mice received saline solution only. For immunohistochemistry, mice were euthanized with 100 mg/kg pentobarbital and transcardially perfused first with 50 ml of heparin solution (5 U/ml) and then with 100 ml of 4% paraformaldehyde. Brain and spleen free-floating sections were prepared as described elsewhere (54). For HPLC analysis of MPP+ levels, brains were rapidly removed from the skull and striata were dissected on humidified filters at 4°C. Tissues were then immersed in appropriate buffer.

Passive transfers.

Single-cell suspensions were prepared from spleen and/or lymph nodes isolated from Tie2-Cre+/ZEG+, gld, Ifng–/–, or C57BL/6J mice. GFP+ T and B cells were purified with a cell magnetic separator (MACS, Miltenyi Biotech) according to the manufacturer’s procedure, using anti-TCRβ (H57-597), anti-CD3ε (145-2C11), anti-CD4 (H-129.19), anti-CD8α (53-6.7), and anti-B220 PE-conjugated antibodies (all from BD Biosciences — Pharmingen) and anti–PE-conjugated MicroBeads (Miltenyi Biotech). Cells labeled with MicroBeads were retained on the MACS Column while unlabeled cells passed through. The column was removed from the separator, and the retained cells were eluted as the enriched, positively selected cell fraction. The enrichment of cells was confirmed by flow cytometry analysis using a FACSCalibur (Becton Dickinson) (e.g., more than 95% for T cells; Supplemental Figure 2A). Recipient Rag1–/– mice received a single i.v. injection of either 107 GFP+ T cells or 2.5 107 GFP+ B cells or 2 injections, 4 hours apart, of 107 total splenocytes (either gld, Ifng–/–, or WT) in 0.2 ml phosphate buffered saline solution. Reconstitutions of GFP-expressing T and B lymphocytes in Rag1–/– recipient mice were checked by FACS analysis of blood samples collected from reconstituted Rag1–/– recipient mice prior to MPTP treatment or from lymph nodes after the mice were sacrificed (Supplemental Figure 2C). Three to four weeks after transfer, mice were intoxicated with MPTP or received an equal volume of saline solution.


Human sections were first deparaffinized in 2 changes of xylene for 5 minutes each. They were hydrated in 2 changes of 100%, 95%, then 75% ethanol and rinsed in distilled water. Antigen demasking was performed at 90°C–95°C for 30 minutes in citrate buffer, pH 6, (for CD8, CD20, CD79a, and CD57 staining) or EDTA buffer, pH 8, for CD4 staining. Sections were then allowed to cool down for 20 minutes before being rinsed in 0.25 M Tris buffer.

Human sections were pretreated with 0.01% H2O2/20% methanol, followed by 0.5% Triton and by normal goat serum (1:30; 30 minutes). They were then incubated at 4°C for 48 hours with anti-CD8 (1:50; Dako), anti-CD4 (1:20; Novocastra), anti-CD79α (1:100; Novocastra), anti-CD20 (1:100; L26, Novocastra), or anti-CD57 (1:50; Zymed).

Immunohistochemical staining on mouse brain sections was performed as previously described (51). The following primary antibodies were used: anti-TH (1:1,000; Peel Freez Biochemicals), anti–Mac-1/CD11b (1:250; Serotec), anti-GFAP (astrocytes, 1:5,000; Dako), anti-GFP (1:1,000; Invitrogen), anti-CD3 (1:1,000; Serotec), anti-CD8 (1:100; Serotec), or anti-CD4 (1:100; Serotec). Staining was revealed by the ABC method (Vector Laboratories) with 3,3ι-diaminobenzidine (DAB) as the peroxidase substrate. Mouse sections were counterstained with thionin solution (Nissl stain), whereas human sections were counterstained with H&E solution.

For double-staining experiments, brain sections were simultaneously incubated with 2 primary antibodies developed in different species: anti-TH (1:1,000; Peel Freez Biochemicals), anti-GFP (1:1,000; Invitrogen), anti–Glut-1 (1:300; Santa Cruz Biotechnology Inc.), anti-PCNA (1:500; Dako), anti–Mac-1 (1:250; Serotec), anti-GFAP (1:5000; Dako), anti-CD3 (1:1,000; Serotec), anti-CD8 (1:100; Serotec), anti-CD4 (1:100; Serotec), anti–ICAM-1 (1:50; Serotec), anti-albumin (1:1,000; Cappel, MP Biomedicals), and anti-p17 caspase-3 (R&D Systems). Sections were then incubated in specific CY3- or FITC-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories Inc.) at 1:250 dilution for 90 minutes at room temperature. For PCNA staining, sections were pretreated in 30% ethanol for 2 minutes and 70% ethanol at –20°C for 20 minutes. Hoechst nuclear staining was performed as previously described (53).

Electron microscopy.

Ultrastructural analysis of T cells in the SNpc was performed as previously described with minor modifications (55). In brief, small blocks of mesencephalon containing the SNpc were fixed in a mixture of 4% paraformaldehyde and 2.5% glutaraldehyde. Sections 50-μm thick were cut and labeled for CD8 as described above. Following identification of CD8+ cells, small areas of the sections were then excised and post-fixed in 1% osmium tetroxide for 30 minutes, rinsed in distilled water, dehydrated in a graded series of ethanol solutions, and embedded in Epon. Ultrathin (70 nm) sections were cut, counterstained with conventional techniques, and analyzed with a JEOL 1200EX II electron microscope at 80 kV.

Measurement of striatal dopamine.

Striatal levels of dopamine and its metabolites (DOPAC, HVA) were determined by HPLC as previously reported (42).

Measurement of striatal MPP+.

Mice were killed 90 minutes after 1 i.p. injection of 30 mg/kg MPTP-HCl, and their striata were recovered and processed for HPLC, using UV detection (295-nm wavelength) to measure MPP+ as described elsewhere (56).

Antibody array.

C57BL/6J mice (n = 5 per group) were intoxicated with MPTP and sacrificed from 12 hours to 7 days after the last injection. Controls received an equal volume of saline solution. The expression level of various cytokines in protein homogenates prepared from the ventral mesencephalon was analyzed using a mouse antibody array glass chip (RayBio Mouse Cytokine Antibody Array G series 1000, RayBiotech Inc.). Incubation and washes were done according to the manufacturer’s instructions. Briefly, chip arrays were blocked at room temperature for 30 minutes before being incubated with 50–100 μl of each sample at room temperature for 2 hours. Glass chips were then washed and incubated with biotin-conjugated primary antibody and Alexa Fluor 555–conjugated streptavidin according to the manufacturer’s instructions. Fluorescence detection and analysis were performed using an Axon GenePix laser scanner.

Image and data analysis.

DAB-immunostained sections were analyzed by bright-field microscopy, using a Leitz microscope equipped with image analysis software (Mercator, ExploraNova). TH+ and Nissl+ cell bodies were quantified stereologically on regularly spaced sections covering the whole SNpc using the VisioScan stereology tool. The investigator performing the quantification was blinded to the treatment and genotype groups during the analysis. Fluorescent sections were analyzed on a Zeiss Axioplan 2 using ExploraNova FluoUp 1.0 software.


All values are expressed as the mean ± SEM. Differences in means between 2 groups were analyzed using 2-tailed Student’s t test or, when data were not normally distributed, with a nonparametric Mann-Whitney U test. Differences in means among multiple data sets were analyzed using 1- or 2-way ANOVA with time, treatment, or genotype as the independent factors. When ANOVA showed significant differences, pair-wise comparisons between means were tested by Tukey post-hoc analysis. When data were not normally distributed, ANOVA on ranks was used (Kruskal-Wallis test followed by pairwise comparison using Dunn test). In all analyses, P values of less than 0.05 were considered significant (SigmaStat Statistical Software, Jandel Scientific).

Supplementary Material

Supplemental data:


We thank C. Combadière and C. Lobsiger for helpful discussions, V. Sazdovitch for assistance in collecting postmortem material, and T. Welte for providing Tie2-Cre+/ZEG+ double transgenic mice. This work was supported by grants from The Michael J. Fox Foundation (S. Hunot and E.C. Hirsch), Fondation pour la Recherche sur le Cerveau (S. Hunot), Fondation France Parkinson (V. Brochard), and the German Academic Exchange Service (D. Alvarez-Fischer). R.A. Flavell is an investigator at the Howard Hughes Medical Institute. E.C. Hirsch and S. Hunot are investigators at the Centre National de la Recherche Scientifique (CNRS).


Conflict of interest: The authors have declared that no conflict of interest exists.

Nonstandard abbreviations used: BBB, blood-brain barrier; DN, dopamine-containing neuron; GFAP, glial fibrillary acidic protein; gld, FasL-mutated generalized lymphoproliferative; MPP+, 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PCNA, proliferating cell nuclear antigen; PD, Parkinson disease; Rag1, recombinase activating gene 1; SN, substantia nigra; SNpc, SN pars compacta; α-Syn, α-synuclein; Tc, cytotoxic T cell; Tcrb, T cell receptor β chain; TH, tyrosine hydroxylase.

Citation for this article: J. Clin. Invest. 119:182–192 (2009). doi:10.1172/JCI36470

See the related Commentary beginning on page 13.


1. Dauer W., Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909. doi: 10.1016/S0896-6273(03)00568-3. [PubMed] [Cross Ref]
2. Chen H., et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann. Neurol. 2005;58:963–967. doi: 10.1002/ana.20682. [PubMed] [Cross Ref]
3. Wahner A.D., Bronstein J.M., Bordelon Y.M., Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology. 2007;69:1836–1842. doi: 10.1212/ [PubMed] [Cross Ref]
4. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson’s disease. J. Neural Transm. Suppl. 2000;60:277–290. [PubMed]
5. Czlonkowska A., Kurkowska-Jastrzebska I., Czlonkowski A., Peter D., Stefano G.B. Immune processes in the pathogenesis of Parkinson’s disease — a potential role for microglia and nitric oxide. Med. Sci. Monit. 2002;8:RA165–RA177. [PubMed]
6. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br. J. Pharmacol. 2007;150:963–976. doi: 10.1038/sj.bjp.0707167. [PMC free article] [PubMed] [Cross Ref]
7. McGeer P.L., Itagaki S., Akiyama H., McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 1988;24:574–576. doi: 10.1002/ana.410240415. [PubMed] [Cross Ref]
8. Hunot S., et al. FcεRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells. J. Neurosci. 1999;19:3440–3447. [PubMed]
9. Kurkowska-Jastrzebska I., et al. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 1999;156:50–61. doi: 10.1006/exnr.1998.6993. [PubMed] [Cross Ref]
10. Janeway, C.A., Jr., and Travers, P. 1997. Immunobiology: the immune system in health and disease. 3rd edition. Garland Publishing Inc. New York, New York, USA. A1–A10.
11. Kortekaas R., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 2005;57:176–179. doi: 10.1002/ana.20369. [PubMed] [Cross Ref]
12. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J. Neural Transm. 2006;113:477–485. doi: 10.1007/s00702-005-0409-y. [PubMed] [Cross Ref]
13. Serpe C.J., Kohm A.P., Huppenbauer C.B., Sanders V.M., Jones K.J. Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. . J. Neurosci. 1999;19:RC7. [PubMed]
14. Chen Z., Ljunggren H.G., Zhu S.W., Winblad B., Zhu J. Reduced susceptibility to kainic acid-induced excitotoxicity in T-cell deficient CD4/CD8 (–/–) and middle-aged C57BL/6 mice. . J. Neuroimmunol. . 2004;146:33–38. doi: 10.1016/j.jneuroim.2003.09.015. [PubMed] [Cross Ref]
15. Mombaerts P., et al. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature. . 1992;360:225–231. doi: 10.1038/360225a0. [PubMed] [Cross Ref]
16. Fung-Leung W.P., et al. CD8 is needed for development of cytotoxic T-cells but not helper T-cells. Cell. 1991;65:443–449. doi: 10.1016/0092-8674(91)90462-8. [PubMed] [Cross Ref]
17. Rahemtulla A., et al. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature. 1991;353:180–184. doi: 10.1038/353180a0. [PubMed] [Cross Ref]
18. Mount M.P., et al. Involvement of interferon-γ in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 2007;27:3328–3337. doi: 10.1523/JNEUROSCI.5321-06.2007. [PubMed] [Cross Ref]
19. Takahashi T., et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. . 1994;76:969–976. doi: 10.1016/0092-8674(94)90375-1. [PubMed] [Cross Ref]
20. Hunot S., Hirsch E.C. Neuroinflammatory processes in Parkinson’s disease. Ann. Neurol. 2003;53(Suppl. 3):S49–S60. [PubMed]
21. Baba Y., Kuroiwa A., Uitti R.G., Wszolek Z.K., Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 2005;11:493–498. doi: 10.1016/j.parkreldis.2005.07.005. [PubMed] [Cross Ref]
22. Cose S., Brammer C., Khanna K.M., Masopust D., Lefrançois L. Evidence that a significant number of naive T cells enter non-lymphoid organs as part of a normal migratory pathway. Eur. J. Immunol. 2006;36:1423–1433. doi: 10.1002/eji.200535539. [PubMed] [Cross Ref]
23. Togo T., et al. Occurrence of T cells in the brain of Alzheimer’s disease and other neurological diseases. J. Neuroimmunol. 2002;124:83–92. doi: 10.1016/S0165-5728(01)00496-9. [PubMed] [Cross Ref]
24. German D.C., et al. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration. 1996;5:299–312. doi: 10.1006/neur.1996.0041. [PubMed] [Cross Ref]
25. Farkas E., De Jong G.I., de Vos R.A., Jansen Steur E.N., Luiten P.G. Pathological features of cerebral cortical capillaries are double in Alzheimer’s disease and Parkinson’s disease. Acta Neuropathol. 2000;100:395–402. doi: 10.1007/s004010000195. [PubMed] [Cross Ref]
26. Haussermann P., Kuhn W., Przuntek H., Muller T. Integrity of the blood-cerebrospinal fluid barrier in early Parkinson’s disease. Neurosci. Lett. 2001;300:182–184. doi: 10.1016/S0304-3940(01)01574-9. [PubMed] [Cross Ref]
27. Adams J.D., Jr., Klaidman L.K., Odunze I.N., Johannenssen J.N. Effects of MPTP on the cerebrovasculature. Int. J. Dev. Neurosci. 1991;9:155–159. doi: 10.1016/0736-5748(91)90006-8. [PubMed] [Cross Ref]
28. Zhao C., Ling Z., Newman M.B., Bhatia A., Carvey P.M. TNF-α knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol. Dis. 2007;26:36–46. doi: 10.1016/j.nbd.2006.11.012. [PMC free article] [PubMed] [Cross Ref]
29. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301–314. doi: 10.1016/0092-8674(94)90337-9. [PubMed] [Cross Ref]
30. Miklossy J., et al. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 2005;197:275–283. doi: 10.1016/j.expneurol.2005.10.034. [PubMed] [Cross Ref]
31. Jenner P., Olanow C.W. Understanding cell death in Parkinson’s disease. Ann. Neurol. 1998;44(Suppl. 1):S72–S84. [PubMed]
32. Benner E.J., et al. Nitrated α-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PloS ONE. 2008;3:e1376. [PMC free article] [PubMed]
33. Ciesielska A., et al. Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson’s disease. Acta Neurobiol. Exp. (Wars.) 2003;63:117–126. [PubMed]
34. Hayley S., et al. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J. Neurosci. 2004;24:2045–2053. doi: 10.1523/JNEUROSCI.4564-03.2004. [PubMed] [Cross Ref]
35. Landau A.M., et al. Defective Fas expression exacerbates neurotoxicity in a model of Parkinson’s disease. J. Exp. Med. 2005;202:575–581. doi: 10.1084/jem.20050163. [PMC free article] [PubMed] [Cross Ref]
36. Ashany D., et al. Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Proc. Natl. Acad. Sci. U. S. A. 1995;92:11225–11229. doi: 10.1073/pnas.92.24.11225. [PubMed] [Cross Ref]
37. Park D.R., et al. Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J. Immunol. 2003;170:6209–6216. [PubMed]
38. Choi C., Benveniste E.N. Fas ligand/fas system in the brain: regulator of immune and apoptosis responses. Brain Res. Rev. 2004;44:65–81. doi: 10.1016/j.brainresrev.2003.08.007. [PubMed] [Cross Ref]
39. Ferrer I., Blanco R., Cutillas B., Ambrosio S. Fas and Fas-L expression in Huntington’s disease and Parkinson’s disease. Neuropathol. Appl. Neurobiol. 2000;26:424–433. doi: 10.1046/j.1365-2990.2000.00267.x. [PubMed] [Cross Ref]
40. Giuliani F., Goodyer C.G., Antel J.P., Yong V.W. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 2003;171:368–379. [PubMed]
41. Ju S.T., Cui H., Panka D.J., Ettinger R., Marshak-Rothstein A. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 1994;91:4185–4189. doi: 10.1073/pnas.91.10.4185. [PubMed] [Cross Ref]
42. Rousselet E., et al. Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp. Neurol. 2002;177:183–192. doi: 10.1006/exnr.2002.7960. [PubMed] [Cross Ref]
43. Ferger B., Leng A., Mura A., Hengerer B., Feldon J. Genetic ablation of tumor necrosis factor–alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 2004;89:822–833. doi: 10.1111/j.1471-4159.2004.02399.x. [PubMed] [Cross Ref]
44. Sriram K., Miller D.B., O’Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 2006;96:706–718. doi: 10.1111/j.1471-4159.2005.03566.x. [PubMed] [Cross Ref]
45. Zhu J., Paul W.E. CD4 T cells: fates, functions, and faults. Blood. 2008;112:1557–1568. doi: 10.1182/blood-2008-05-078154. [PubMed] [Cross Ref]
46. Kebir H., et al. Human Th17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007;13:1173–1175. doi: 10.1038/nm1651. [PubMed] [Cross Ref]
47. Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U. S. A. 2008;105:15558–15563. doi: 10.1073/pnas.0807419105. [PubMed] [Cross Ref]
48. Banerjee R., et al. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS ONE. 2008;3:e2740. [PMC free article] [PubMed]
49. Benner E.J., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc. Natl. Acad. Sci. U. S. A. 2004;101:9435–9440. doi: 10.1073/pnas.0400569101. [PubMed] [Cross Ref]
50. Reynolds A.D., et al. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J. Leukoc. Biol. 2007;82:1083–1094. doi: 10.1189/jlb.0507296. [PubMed] [Cross Ref]
51. Luster A.D., Alon R., von Andrian U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 2005;6:1182–1190. doi: 10.1038/ni1275. [PubMed] [Cross Ref]
52. Braak H., Del Tredici K. Assessing fetal nerve cell grafts in Parkinson’s disease. Nat. Med. 2008;14:483–485. doi: 10.1038/nm0508-483. [PubMed] [Cross Ref]
53. Welte T., et al. STAT3 deletion during hematopoiesis causes Crohn’s disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity. Proc. Natl. Acad. Sci. U. S. A. 2003;100:1879–1884. doi: 10.1073/pnas.0237137100. [PubMed] [Cross Ref]
54. Hunot S., et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson’s disease. Proc. Natl. Acad. Sci. U. S. A. 2004;101:665–670. doi: 10.1073/pnas.0307453101. [PubMed] [Cross Ref]
55. Hunot S., et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1997;94:7531–7536. doi: 10.1073/pnas.94.14.7531. [PubMed] [Cross Ref]
56. Liberatore G.T., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999;5:1403–1409. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation